Pelargonium (Umcka) — Research Profile

Pelargonium (Umcka) has stronger clinical evidence than most herbal cold remedies, rivaled only by andrographis. Its unique advantage is combined antiviral and antibacterial activity, which is particularly valuable because many colds progress to secondary bacterial infections (sinusitis, bronchitis). While zinc and vitamin C are also well-proven, Umcka targets respiratory symptoms specifically and is the best-studied herbal remedy for bronchitis. It can be combined with zinc and vitamin C for comprehensive coverage.

EPs 7630 has been studied in multiple pediatric clinical trials and is approved for children over 1 year of age in Germany. The Cochrane review included pediatric studies that showed both efficacy and good tolerability. Umcka-branded products offer age-specific dosing for children. As with all supplements, consult your pediatrician before starting, particularly for children under 6 years.

Germany has a well-established phytomedicine regulatory framework (Commission E) that allows herbal medicines to be registered as licensed drugs based on clinical trial evidence. EPs 7630 has achieved this status, making it available in pharmacies as a recognized medicine. In the US, it is sold as a dietary supplement (Umcka Cold Care brand) with less regulatory recognition. The clinical evidence is the same regardless of geography — it is simply better known and more integrated into medical practice in European countries.

The liquid EPs 7630 extract has the strongest evidence: in the Cochrane review the liquid preparation improved most acute-bronchitis outcomes whereas tablets did not clearly do so. The EMA recognizes both liquid and dry-extract (tablet) forms but specifies that children under 6 should use only the liquid. There is no basis for a 'best' form beyond matching EPs 7630 standardization, so choose the liquid if you want the better-supported preparation.

The best-supported use is shortening and easing the symptoms of acute respiratory infections. A Cochrane review found EPs 7630 liquid effective for most symptoms of acute bronchitis in adults and children, beneficial in acute rhinosinusitis (complete resolution by day 21, RR 0.43, 95% CI 0.30-0.62), and helpful for the common cold by day 10, though it rated the overall evidence low to very low quality. It is a symptom-duration remedy, not a proven means of preventing or curing infection.

Per the EMA monograph, adults and adolescents over 12 take the liquid extract at 1.4 ml three times daily (4.2 ml/day) or the dry extract at 20 mg three times daily (60 mg/day). Children 6-12 use 0.9 ml three times daily (2.7 ml/day) of the liquid, and children 3-5 use 0.4 ml three times daily (1.2 ml/day); it is not recommended under age 3. Do not continue beyond 1 week without medical advice.

The standard schedule is three doses spread across the day, started as soon as cold or bronchitis symptoms appear, since the trials dosed three times daily over roughly a week. Morning-versus-evening timing has never been directly compared, so no particular time of day is established as best. Beginning at the first sign of illness is far more relevant to the outcome than the clock time of each dose.

The EMA lists gastrointestinal effects (diarrhoea, epigastric pain, nausea, vomiting, gingival bleeding), nosebleeds, and allergic skin reactions (rash, itching, hives, angioedema), plus rare hypersensitivity or anaphylactic reactions, all at unknown frequency. More seriously, hepatotoxicity and hepatitis have been reported, so stop the product immediately and see a doctor if signs of liver trouble such as jaundice, dark urine, or right-upper-abdominal pain develop. In trials, adverse events were more common than with placebo but none were serious.

The EMA monograph reports no documented interactions between pelargonium root and other medicines. However, because bleeding-related effects such as nosebleeds and gum bleeding are on its side-effect list, caution is reasonable if you take anticoagulant or antiplatelet drugs, even though no specific interaction has been confirmed. Given the liver-injury reports, also be careful combining it with other medications that can stress the liver.

It is aimed at otherwise-healthy adults and children aged 3 and older who want to ease symptoms and shorten an acute cold or bronchitis, taken as a short course at the first sign of illness. It should be avoided by anyone hypersensitive to it, and the EMA does not recommend it during pregnancy or breastfeeding or in children under 3. People with existing liver disease should be especially cautious given the reported hepatotoxicity.

Pelargonium is a short-course remedy for acute infections, not a daily tonic, so trials dosed it over roughly 7 days and tracked symptom improvement across that window. In a Cochrane review of EPs 7630, the liquid extract improved most acute-bronchitis symptoms over about a week, and for the common cold a benefit appeared by day 10 but not at day 5. Expect cough and congestion to ease gradually over several days rather than the same day; the EMA advises seeing a clinician if symptoms persist beyond 1 week.

It is not meant for long-term daily use: the EMA classifies pelargonium root as a traditional remedy for the symptomatic treatment of the common cold and directs users to consult a doctor if symptoms last longer than 1 week. Clinical trials evaluated only short courses of about 7 days, so ongoing daily use has not been studied and no safety data support it. Because hepatotoxicity and hepatitis cases have been reported with these products, extended self-treatment is specifically discouraged.

The EMA monograph states no case of overdose has been reported, but that is not a reason to exceed labelled amounts. Standardized traditional doses are modest, 1.4 ml of the liquid extract or 20 mg of dry extract three times daily for adults, and taking more mainly raises the chance of the known side effects (stomach upset, nosebleeds, gum bleeding, allergic reactions) without added benefit. Stop immediately and seek care if any signs of liver problems appear.

No specific supplement combinations have been formally studied, and the EMA lists no documented interactions for pelargonium root. Because its reported adverse effects include nosebleeds and gum bleeding, pairing it with other agents that can affect bleeding (for example high-dose fish oil or vitamin E) warrants caution even though no defined interaction exists. Given the liver-injury reports, also avoid stacking it with other products that carry hepatotoxic potential.

Look for products standardized to the clinically studied extract EPs 7630, made from Pelargonium sidoides root, since that is the specific preparation used in the acute respiratory-infection trials. The EMA-recognized forms are a liquid extract (drug-extract ratio 1:8-10, 11% ethanol) and dry extracts (DER 4-25:1 or 4-7:1), and the label should state the per-dose amount in ml or mg. Note the liquid form contains ethanol, which matters for children and anyone avoiding alcohol.